{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:57:56Z","timestamp":1777111076346,"version":"3.51.4"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Levosulpiride and omeprazole are co-prescribed for gastrointestinal disorders associated with depression and anxiety. Objective of the study was to develop a sensitive, robust and simple method for simultaneous analysis of levosulpiride and omeprazole in human plasma and applicability of the method in determination of pharmacokinetics drug-drug interaction. In the presented study, a reversed-phase HPLC-UV method was developed for the simultaneous determination of levosulpiride and omeprazole using pantoprazole as the internal standard. Experimental conditions were optimized and the developed method was validated as per standard guidelines (USP and ICH). Furthermore, the developed method was applied for evaluation of pharmacokinetics drug-drug interaction between levosulpiride (50 mg) and omeprazole (40 mg) in healthy human volunteers. Sharpsil C8 column (4.6 \u00d7 250 mm, 5 \u03bcm), Ultisil C8 column (4.6 mm \u00d7 150 mm, 5 \u03bcm) and Agilent C18 column (4.6 \u00d7 250 mm, 5 \u03bcm) were evaluated as stationary phase. The best resolution was achieved with Agilent C18 (4.6 x 250 mm, 5 \u03bcm) column and was selected for further study. The mobile phase consisted of a mixture of acetonitrile and phosphate buffer (pH 7.2) in 60:40 by volume, and was pumped at a flow rate of 1 mL\/min. Detector wavelength was set at 280 nm. Levosulpiride and omeprazole were extracted from human plasma with ethyl acetate and dichloromethane (4:1, v\/v). The calibration curves for both levosulpiride (5\u2013150 ng\/mL) and omeprazole (10\u20131500 ng\/mL) were linear. The lower limit of quantification and limit of detection for levosulpiride were 5 and 2 ng\/mL, while for omeprazole these were 10 and 3 ng\/mL, respectively. Pharmacokinetics analysis showed that co-administration of omeprazole increased the AUC and C<jats:sub>max<\/jats:sub> of levosulpiride, while the clearance was reduced. Both the changes were insignificant. Similarly, no significant change in the pharmacokinetic parameters of omeprazole was observed with co-administration of levosulpiride.<\/jats:p>","DOI":"10.1371\/journal.pone.0309453","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T17:58:08Z","timestamp":1724954288000},"page":"e0309453","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development and validation of a reversed-phase HPLC-UV method for simultaneous determination of levosulpiride and omeprazole in human plasma: Applicability of the method for evaluation of pharmacokinetic drug-drug interactions"],"prefix":"10.1371","volume":"19","author":[{"given":"Muhammad","family":"Hashim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7722-0392","authenticated-orcid":true,"given":"Lateef","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4121-2400","authenticated-orcid":true,"given":"Amjad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Faheem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"issue":"1","key":"pone.0309453.ref001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cgh.2006.09.016","article-title":"Time trends of gastroesophageal reflux disease: a systematic review","volume":"5","author":"H.B. El\u2013Serag","year":"2007","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"5","key":"pone.0309453.ref002","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/j.gastro.2012.08.002","article-title":"Burden of gastrointestinal disease in the United States: 2012 update","volume":"143","author":"A.F. Peery","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"pone.0309453.ref003","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study","volume":"160","author":"A.D. Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"pone.0309453.ref004","first-page":"1029","article-title":"Drugs used in the treatment of gastrointestinal diseases","volume":"10","author":"K.R. McQuaid","year":"2018","journal-title":"Basic and clinical pharmacology"},{"issue":"4","key":"pone.0309453.ref005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1472-8206.2005.00348.x","article-title":"Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels","volume":"19","author":"F.D. Mario","year":"2005","journal-title":"Fundamental & clinical pharmacology"},{"issue":"4","key":"pone.0309453.ref006","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update","volume":"37","author":"R.-S. Wedemeyer","year":"2014","journal-title":"Drug safety"},{"issue":"11","key":"pone.0309453.ref007","doi-asserted-by":"crossref","first-page":"e040473","DOI":"10.1136\/bmjopen-2020-040473","article-title":"Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study","volume":"10","author":"Y. Liu","year":"2020","journal-title":"BMJ open"},{"issue":"suppl 2","key":"pone.0309453.ref008","first-page":"II25","article-title":"Psychosocial aspects of the functional gastrointestinal disorders","volume":"45","author":"D.A. Drossman","year":"1999","journal-title":"Gut"},{"issue":"2","key":"pone.0309453.ref009","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10388-022-00960-3","article-title":"Causal effect of anxiety and depression status on the symptoms of gastroesophageal reflux disease and functional dyspepsia during proton pump inhibitor therapy","volume":"20","author":"K. Nakada","year":"2023","journal-title":"Esophagus"},{"issue":"2","key":"pone.0309453.ref010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/1043-6618(95)80053-0","article-title":"Levosulpiride: a review of its clinical use in psychiatry","volume":"31","author":"A. Mucci","year":"1995","journal-title":"Pharmacological research"},{"key":"pone.0309453.ref011","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF02245639","article-title":"Chronic administration of l-sulpiride at non-neuroleptic doses reduces the duration of immobility in experimental models of \u201cdepression-like\u201d behavior","volume":"121","author":"A. Vergoni","year":"1995","journal-title":"Psychopharmacology"},{"issue":"2","key":"pone.0309453.ref012","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/FTD.0000000000000380","article-title":"Bioequivalence of a New Oral Levosulpiride Formulation Compared With a Standard One in Healthy Volunteers","volume":"39","author":"S. De Gregori","year":"2017","journal-title":"Therapeutic Drug Monitoring"},{"issue":"1","key":"pone.0309453.ref013","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/bdd.2308","article-title":"Influence of piperine and omeprazole on the regional absorption of Daclatasvir from rabbit intestine","volume":"43","author":"S.M. Ashmawy","year":"2022","journal-title":"Biopharmaceutics & Drug Disposition"},{"issue":"1","key":"pone.0309453.ref014","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/10408347.2020.1791042","article-title":"Recent Analytical Methodologies for the Determination of Omeprazole and\/or Its Active Isomer Esomeprazole in Different Matrices: A Critical Review","volume":"52","author":"E.I. El-Kimary","year":"2022","journal-title":"Critical Reviews in Analytical Chemistry"},{"issue":"12","key":"pone.0309453.ref015","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/bmc.1260","article-title":"Rapid quantification of levosulpiride in human plasma using RP\u2010HPLC\u2010MS\/MS for pharmacokinetic and bioequivalence study","volume":"23","author":"J.H. Park","year":"2009","journal-title":"Biomedical Chromatography"},{"issue":"2","key":"pone.0309453.ref016","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1570-0232(04)00566-5","article-title":"Hydrophilic interaction liquid chromatography\u2013tandem mass spectrometry for the determination of levosulpiride in human plasma","volume":"809","author":"I.B. Paek","year":"2004","journal-title":"Journal of Chromatography B"},{"issue":"3","key":"pone.0309453.ref017","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jpha.2016.01.001","article-title":"Development and validation of a high throughput UPLC\u2013MS\/MS method for simultaneous quantification of esomeprazole, rabeprazole and levosulpiride in human plasma","volume":"6","author":"R.H.B. Chunduri","year":"2016","journal-title":"Journal of Pharmaceutical Analysis"},{"issue":"4","key":"pone.0309453.ref018","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jpba.2004.02.024","article-title":"Development of HPLC method for the determination of levosulpiride in human plasma","volume":"35","author":"S.-E. Jin","year":"2004","journal-title":"Journal of pharmaceutical and biomedical analysis"},{"key":"pone.0309453.ref019","volume-title":"Bioanalytical method validation and study sample analysis M10","author":"I.H. Guideline","year":"2022"},{"issue":"1\u20132","key":"pone.0309453.ref020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jchromb.2005.11.036","article-title":"Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography\u2013mass spectrometry","volume":"831","author":"U. Hofmann","year":"2006","journal-title":"Journal of Chromatography B"},{"issue":"15","key":"pone.0309453.ref021","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1080\/10826076.2011.569807","article-title":"Optimization and validation of HPLC-UV method for simultaneous determination of omeprazole and its metabolites in human plasma: effects of various experimental conditions and parameters","volume":"34","author":"L. Ahmad","year":"2011","journal-title":"Journal of liquid chromatography & related technologies"},{"issue":"7","key":"pone.0309453.ref022","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1590-8658(02)80102-5","article-title":"Proton pump inhibitors-differences emerge in hepatic metabolism","volume":"34","author":"K. McColl","year":"2002","journal-title":"Digestive and Liver Disease"},{"issue":"2","key":"pone.0309453.ref023","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3797\/scipharm.1310-17","article-title":"Development and Validation of a UPLC Method by the QbD-Approach for the Estimation of Rabeprazole and Levosulpiride from Capsules","volume":"82","author":"V.R.R. Thummala","year":"2014","journal-title":"Scientia Pharmaceutica"},{"issue":"4","key":"pone.0309453.ref024","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jpba.2007.04.022","article-title":"Analytical methodologies for the determination of omeprazole: an overview","volume":"44","author":"M.E. Bosch","year":"2007","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"2","key":"pone.0309453.ref025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jchromb.2003.07.009","article-title":"Improvement and validation of a liquid chromatographic method for the determination of levosulpiride in human serum and urine","volume":"796","author":"H.-Y. Cho","year":"2003","journal-title":"Journal of Chromatography B"},{"issue":"1","key":"pone.0309453.ref026","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/10837450.2017.1419256","article-title":"Development and characterisation of levosulpiride-loaded suppositories with improved bioavailability in vivo","volume":"24","author":"Fakhar-ud-Din","year":"2019","journal-title":"Pharmaceutical development and technology"},{"issue":"1","key":"pone.0309453.ref027","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.neuroscience.2010.04.065","article-title":"Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects","volume":"169","author":"H. Cho","year":"2010","journal-title":"Neuroscience"},{"key":"pone.0309453.ref028","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00210-001-0489-7","article-title":"Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein","volume":"364","author":"C. Pauli-Magnus","year":"2001","journal-title":"Naunyn-Schmiedeberg\u2019s archives of pharmacology"},{"key":"pone.0309453.ref029","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s13318-018-0519-1","article-title":"Mechanistic assessment of the effect of omeprazole on the in vivo pharmacokinetics of itraconazole in healthy volunteers","volume":"44","author":"A.Y. Abuhelwa","year":"2019","journal-title":"European journal of drug metabolism and pharmacokinetics"},{"issue":"11","key":"pone.0309453.ref030","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1016\/j.clinthera.2015.08.024","article-title":"Tolerability and pharmacokinetic comparison of oral, intramuscular, and intravenous administration of levosulpiride after single and multiple dosing in healthy Chinese volunteers","volume":"37","author":"M. Xu","year":"2015","journal-title":"Clinical therapeutics"},{"key":"pone.0309453.ref031","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00044011-200019020-00008","article-title":"Levosulpiride for dyspepsia and emesis: a review of its pharmacology, efficacy and tolerability","volume":"19","author":"G. Corazza","year":"2000","journal-title":"Clinical Drug Investigation"},{"issue":"15","key":"pone.0309453.ref032","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1002\/mds.22805","article-title":"Levosulpiride\u2010induced movement disorders","volume":"24","author":"H.W. Shin","year":"2009","journal-title":"Movement disorders: official journal of the Movement Disorder Society"},{"issue":"5","key":"pone.0309453.ref033","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1365-2036.2000.00742.x","article-title":"Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis","volume":"14","author":"C. Mansi","year":"2000","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"11","key":"pone.0309453.ref034","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1185\/03007995.2011.624088","article-title":"Relative bioavailability of a 5 mg mosapride\/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study","volume":"27","author":"G. Keller","year":"2011","journal-title":"Current medical research and opinion"},{"issue":"10","key":"pone.0309453.ref035","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11015","article-title":"Esomeprazole and apixaban pharmacokinetic interactions in healthy rats","volume":"8","author":"A. Jaber","year":"2022","journal-title":"Heliyon"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T17:58:28Z","timestamp":1724954308000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309453"}},"subtitle":[],"editor":[{"given":"Satish","family":"Rojekar","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0309453","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]}}}